<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012460</article-id><article-id pub-id-type="publisher-id">ACM-39270</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_27438584.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  口服普萘洛尔联合复方倍他米松局部注射治疗婴幼儿血管瘤的疗效评价
  Efficacy Evaluation of Oral Propranolol Combined with Compound Betamethasone Local Injection in the Treatment of Infantile Hemangioma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>耿</surname><given-names>锐</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>耿</surname><given-names>向群</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>毅鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>丹怡</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>晨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>彬</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>振雨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>青岛大学附属医院工会，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院美容整形外科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff3"><addr-line>泰安市中心医院核医学科，山东 泰安</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>3069</fpage><lpage>3075</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：分析普萘洛尔联合倍他米松局部注射治疗婴幼儿血管瘤的临床疗效。方法：收集2018年5月至2020年6月就诊于青岛大学附属医院美容整形外科符合纳入标准的婴幼儿血管瘤患者61例，分组为单纯口服普萘洛尔组共19例，单纯局部注射复方倍他米松组共20例，口服普萘洛尔联合局部注射复方倍他米松治疗组共22例，术后随访观察6个月并评估临床疗效。结果：联合组的治愈率明显高于单纯注射复方倍他米松组和单纯口服普萘洛尔组，差异有统计学意义(P &lt; 0.05)。复方倍他米松组与普萘洛尔组比较，两组治愈率无明显差异(P &gt; 0.05)。联合组治疗时间明显短于单用复方倍他米松组和单用普萘洛尔组，差异有统计学意义(P &lt; 0.05)。单用复方倍他米松组与单用普萘洛尔组患者的治疗时间无差别(P &gt; 0.05)。所有口服普萘洛尔的患儿中有10例出现心率减慢，临床观察后恢复正常，未给予特殊处理。所有注射复方倍他米松的患儿中有6例出现术区肿胀，给予加压包扎后逐渐消退；有2例患儿在注射后出现烦躁。比较三组不良反应的发生率，差异无统计学意义(P &gt; 0.05)。结论：口服普萘洛尔联合局部注射复方倍他米松治疗婴幼儿血管瘤疗效更佳。
    Objective: To analyze the clinical effect of propranolol combined with betamethasone local injection in the treatment of infantile hemangioma. Methods: A total of 61 infants and young children with hemangioma who met the inclusion criteria and visited the Department of Aesthetic and Plastic Surgery, Affiliated Hospital of Qingdao University from May 2018 to June 2020 were collected, there were 19 cases in propranolol group by oral administration alone, 20 cases in compound betamethasone group by local injection alone, and 22 cases in compound betamethasone treatment group by oral propranolol combined with local injection. The postoperative follow-up was observed for 6 months and the clinical efficacy was evaluated. Result: The cure rate of the combined group was significantly higher than that of the compound betamethasone injection group and the propranolol oral injection group, the difference was statistically significant (P &lt; 0.05). There was no significant difference in cure rate between compound betamethasone group and propranolol group (P &gt; 0.05). The duration of treatment in the combination group was significantly shorter than that in the compound betamethasone group and propranolol group alone, with statistically significant difference (P &lt; 0.05). There was no difference in treatment time between compound betamethasone alone and propranolol alone (P &gt; 0.05). Among all the children who took propranolol orally, 10 cases showed slow heart rate, which returned to normal after clinical observation without special treatment. Among all the children injected with compound betamethasone, 6 had swelling in the operative area, which gradually subsided after pressure dressing; two of the children developed dysphoria after injection. The incidence of adverse reactions in the three groups was not statistically significant (P &gt; 0.05). Conclusion: Oral propranolol combined with local injection of compound betamethasone is more effective in the treatment of infantile hemangioma. 
  
 
</p></abstract><kwd-group><kwd>普萘洛尔，倍他米松，婴幼儿血管瘤, Propranolol</kwd><kwd> Betamethasone</kwd><kwd> Infantile Hemangioma</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析普萘洛尔联合倍他米松局部注射治疗婴幼儿血管瘤的临床疗效。方法：收集2018年5月至2020年6月就诊于青岛大学附属医院美容整形外科符合纳入标准的婴幼儿血管瘤患者61例，分组为单纯口服普萘洛尔组共19例，单纯局部注射复方倍他米松组共20例，口服普萘洛尔联合局部注射复方倍他米松治疗组共22例，术后随访观察6个月并评估临床疗效。结果：联合组的治愈率明显高于单纯注射复方倍他米松组和单纯口服普萘洛尔组，差异有统计学意义(P &lt; 0.05)。复方倍他米松组与普萘洛尔组比较，两组治愈率无明显差异(P &gt; 0.05)。联合组治疗时间明显短于单用复方倍他米松组和单用普萘洛尔组，差异有统计学意义(P &lt; 0.05)。单用复方倍他米松组与单用普萘洛尔组患者的治疗时间无差别(P &gt; 0.05)。所有口服普萘洛尔的患儿中有10例出现心率减慢，临床观察后恢复正常，未给予特殊处理。所有注射复方倍他米松的患儿中有6例出现术区肿胀，给予加压包扎后逐渐消退；有2例患儿在注射后出现烦躁。比较三组不良反应的发生率，差异无统计学意义(P &gt; 0.05)。结论：口服普萘洛尔联合局部注射复方倍他米松治疗婴幼儿血管瘤疗效更佳。</p></sec><sec id="s2"><title>关键词</title><p>普萘洛尔，倍他米松，婴幼儿血管瘤</p></sec><sec id="s3"><title>Efficacy Evaluation of Oral Propranolol Combined with Compound Betamethasone Local Injection in the Treatment of Infantile Hemangioma</title><p>Rui Geng<sup>1</sup>, Xiangqun Geng<sup>2</sup>, Yipeng Su<sup>1</sup>, Danyi Li<sup>1</sup>, Chen Sun<sup>1</sup>, Bin Zhang<sup>3</sup>, Zhenyu Chen<sup>1*</sup></p><p><sup>1</sup>Department of Cosmetic and Plastic Surgery, The Hospital Affiliated to Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Nuclear Medicine, The Central Hospital of Taian, Taian Shandong</p><p><sup>3</sup>Department of Labor Union, The Hospital Affiliated to Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/30-1571761x5_hanspub.png" /></p><p>Received: Nov. 21<sup>st</sup>, 2020; accepted: Dec. 15<sup>th</sup>, 2020; published: Dec. 22<sup>nd</sup>, 2020</p><p><img src="//html.hanspub.org/file/30-1571761x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the clinical effect of propranolol combined with betamethasone local injection in the treatment of infantile hemangioma. Methods: A total of 61 infants and young children with hemangioma who met the inclusion criteria and visited the Department of Aesthetic and Plastic Surgery, Affiliated Hospital of Qingdao University from May 2018 to June 2020 were collected, there were 19 cases in propranolol group by oral administration alone, 20 cases in compound betamethasone group by local injection alone, and 22 cases in compound betamethasone treatment group by oral propranolol combined with local injection. The postoperative follow-up was observed for 6 months and the clinical efficacy was evaluated. Result: The cure rate of the combined group was significantly higher than that of the compound betamethasone injection group and the propranolol oral injection group, the difference was statistically significant (P &lt; 0.05). There was no significant difference in cure rate between compound betamethasone group and propranolol group (P &gt; 0.05). The duration of treatment in the combination group was significantly shorter than that in the compound betamethasone group and propranolol group alone, with statistically significant difference (P &lt; 0.05). There was no difference in treatment time between compound betamethasone alone and propranolol alone (P &gt; 0.05). Among all the children who took propranolol orally, 10 cases showed slow heart rate, which returned to normal after clinical observation without special treatment. Among all the children injected with compound betamethasone, 6 had swelling in the operative area, which gradually subsided after pressure dressing; two of the children developed dysphoria after injection. The incidence of adverse reactions in the three groups was not statistically significant (P &gt; 0.05). Conclusion: Oral propranolol combined with local injection of compound betamethasone is more effective in the treatment of infantile hemangioma.</p><p>Keywords:Propranolol, Betamethasone, Infantile Hemangioma</p><disp-formula id="hanspub.39270-formula26"><graphic xlink:href="//html.hanspub.org/file/30-1571761x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/30-1571761x8_hanspub.png" /> <img src="//html.hanspub.org/file/30-1571761x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>婴幼儿血管瘤(Infantile hemangioma, IH)是婴幼儿时期最常见的良性肿瘤，多发现于出生后的几周内，发病率约为4%~5%，男女比例约1:3 [<xref ref-type="bibr" rid="hanspub.39270-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39270-ref2">2</xref>]，瘤体在出生后的最初6个月内即可快速增长至最终面积的80%，后逐渐萎缩，至4岁时大多数患儿的瘤体可完全消退 [<xref ref-type="bibr" rid="hanspub.39270-ref3">3</xref>]。然而，约有5%~10%的患儿在血管瘤进展过程中会出现破溃、感染、疼痛，累及重要器官甚至出现失明、气道梗阻、毁容等严重并发症 [<xref ref-type="bibr" rid="hanspub.39270-ref4">4</xref>]。所以，根据功能性损害及毁容性风险进行评估，大多数学者普遍认为中、高风险的血管瘤应尽早治疗 [<xref ref-type="bibr" rid="hanspub.39270-ref3">3</xref>]。目前治疗婴幼儿血管瘤方法多种多样，主要包括观察等待、药物治疗、激光治疗及手术等 [<xref ref-type="bibr" rid="hanspub.39270-ref5">5</xref>]。自2008年L&#233;aut&#233;-Labr&#232;ze等 [<xref ref-type="bibr" rid="hanspub.39270-ref6">6</xref>] 首次发现普萘洛尔有治疗婴幼儿血管瘤的作用后，单纯口服普萘洛尔逐渐成为治疗IH的一线疗法，但弊端在于治疗时间过长、患儿家属对服用药物后产生潜在并发症的顾虑较多。采用口服糖皮质激素治疗血管瘤始于上世纪60年代 [<xref ref-type="bibr" rid="hanspub.39270-ref7">7</xref>]，为避免系统性用药产生的不良反应，采用瘤体内注射的方式进行用药已成为主流做法 [<xref ref-type="bibr" rid="hanspub.39270-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.39270-ref9">9</xref>]。为缩短治疗时间、降低注射次数及不良反应发生率，我们自2015年开始使用上述两种方式联合治疗婴幼儿血管瘤，疗效较为满意，现将结果进行报道。</p></sec><sec id="s6"><title>2. 研究对象与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>选择2018年5月至2020年6月在青岛大学附属医院美容整形外科诊治的婴幼儿血管瘤患者，共108例。</p><p>纳入标准：1) 所有患儿均通过病史、临床表现、超声等影像学检查确诊为婴幼儿血管瘤；2) 血管瘤均处于增生期；3) 治疗采用本次研究中的3种治疗方案之一；4) 患儿入院前未进行过干预治疗。</p><p>排除标准：1) 患有药物禁忌症，如先天性心脏病、支气管哮喘、心源性休克、心脏传导阻滞、窦性心动过缓、严重感染等；2) 患有其它不适于接受药物治疗的系统性疾病；3) 对β受体阻滞剂和糖皮质激素过敏的患儿；4) 对药物不良反应严重不耐受的患儿；5) 因各种原因中断治疗的患儿；6) 治疗过程中改用其它治疗方法的患儿。根据上述标准共纳入61例患儿，其中男18例，女43例；患者年龄在1月至3岁；根据其采用不同的治疗方案，将患者分为3个治疗组，单纯口服普萘洛尔组19例、单纯局部注射复方倍他米松组20例、口服普萘洛尔联合局部注射复方倍他米松组22例，三组患者的一般资料均无统计学差异(P &gt; 0.05)，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general data of the 3 group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >性别(男/女)</th><th align="center" valign="middle" >年龄(月)</th><th align="center" valign="middle" >治疗前血管瘤面积(mm<sup>2</sup>)</th></tr></thead><tr><td align="center" valign="middle" >倍他米松组</td><td align="center" valign="middle" >4/15</td><td align="center" valign="middle" >13 (10, 21)</td><td align="center" valign="middle" >450 (260, 720)</td></tr><tr><td align="center" valign="middle" >普萘洛尔组</td><td align="center" valign="middle" >7/13</td><td align="center" valign="middle" >12 (6.5, 21.5)</td><td align="center" valign="middle" >650 (318.75, 893.75)</td></tr><tr><td align="center" valign="middle" >联合组</td><td align="center" valign="middle" >7/15</td><td align="center" valign="middle" >13 (5.75, 24.75)</td><td align="center" valign="middle" >650 (288.75, 925)</td></tr><tr><td align="center" valign="middle" >X<sup>2</sup>/H值</td><td align="center" valign="middle" >0.999</td><td align="center" valign="middle" >0.175</td><td align="center" valign="middle" >1.867</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.607</td><td align="center" valign="middle" >0.916</td><td align="center" valign="middle" >0.393</td></tr></tbody></table></table-wrap><p>表1. 3组患儿的一般资料比较</p></sec><sec id="s6_2"><title>2.2. 治疗方法</title><p>所有患儿均在治疗前行血压、血常规、电解质、血糖、肝功、肾功、心肌酶谱、心电图、心脏超声检查，排除支气管哮喘或痉挛、低体重(小于2 kg)、失代偿性心衰、窦性心动过缓、II度及以上房室传导阻滞等用药禁忌。研究方案已得到青岛大学附属医院伦理委员会的同意批准。</p><sec id="s6_2_1"><title>2.2.1. 口服普萘洛尔组</title><p>所有患儿均给予盐酸普萘洛尔片口服，标准治疗剂量为2 mg/kg∙d，分两次口服。初始治疗剂量为1 mg/kg∙d，分两次口服，注意患儿服药后有无四肢冰冷、倦怠嗜睡、呼吸困难等不良反应，如无明显不适，可间隔8~12 h再次给药。次日可增加药量至1.5 mg/kg∙d，分两次给药，继续观察有无不良反应。第3日增加药量至2 mg/kg∙d，如能耐受，后续维持此治疗剂量。服药期间应定期复查，前3个月每4周复查一次，3月后每8周复查一次。每次复查血生化指标、心电图、心脏超声检查、体表肿物超声等；每2周复测体重一次，以调整用药剂量。</p></sec><sec id="s6_2_2"><title>2.2.2. 局部注射复方倍他米松组</title><p>根据病变区域大小选择复方倍他米松注射液(每支1 ml，由二丙酸倍他米松5 mg与倍他来松磷酸钠2 mg组成) 0.5~2 ml，以灭菌注射用水适当稀释，注射器外接带针延长软管(防止针尖位移)，自瘤体表面正常皮肤处穿刺进针，回抽见血液后即可开始注射，采用多点、脉冲式注射的方法，注射完成后外涂红霉素软膏保护术区，加压包扎固定。术后每月复查一次，根据血管瘤消退趋势决定是否再次注射。</p></sec><sec id="s6_2_3"><title>2.2.3. 联合治疗组</title><p>入院后完善相关检查，排除手术禁忌后给予瘤体内注射复方倍他米松治疗，术后第一天开始服用普萘洛尔，用法同普萘洛尔组，若无异常体征可予出院，出院后继续口服普萘洛尔治疗，嘱每月复查一次，评估是否需再次注射治疗及调整普萘洛尔用量。</p></sec></sec><sec id="s6_3"><title>2.3. 疗效评价标准</title><p>全部患儿均随访观察6个月，采用Achauer [<xref ref-type="bibr" rid="hanspub.39270-ref10">10</xref>] 等的方法进行疗效评判，划分4个等级。瘤体缩小 &lt; 25%时，评为I级，疗效差；瘤体缩小26%~50%，评为II级，疗效中；瘤体缩小51%~75%，评为III级，疗效好；瘤体缩小76%~100%，评为IV级，疗效优；以IV级计算治愈率。</p></sec><sec id="s6_4"><title>2.4. 统计学分析</title><p>应用SPSS 24.0软件处理数据。计量资料用中位数或均数&#177;标准差(x &#177; s)表示数据的集中趋势，组间比较服从正态分布使用t检验，不服从正态分布使用wilcoxon秩和检验；计数资料应用百分比和频率表示分类数据分布特征，组间比较采用卡方检验，以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 3组治疗时间比较分析</title><p>单用普萘洛尔、单用复方倍他米松、联合应用复方倍他米松及普萘洛尔三种治疗方案的患者治疗时间有差别(P &lt; 0.01)。经过两两比较，单用复方倍他米松组与单用普萘洛尔组之间患者的治疗时间无差别(P &gt; 0.05)；联合用药组治疗时间明显短于单用复方倍他米松组和单用普萘洛尔组，差异有统计学意义(P &lt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of treatment time among the 3 group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >治疗时间(天)</th></tr></thead><tr><td align="center" valign="middle" >复方倍他米松组</td><td align="center" valign="middle" >143 &#177; 19</td></tr><tr><td align="center" valign="middle" >普萘洛尔组</td><td align="center" valign="middle" >134 &#177; 21</td></tr><tr><td align="center" valign="middle" >联合组</td><td align="center" valign="middle" >80 &#177; 20</td></tr></tbody></table></table-wrap><p>表2. 3组患儿治疗时间比较</p></sec><sec id="s7_2"><title>3.2. 3组治疗效果比较分析</title><p>联合组的治愈率明显高于复方倍他米松组及普萘洛尔组的治愈率，差异有统计学意义(P &lt; 0.01)；复方倍他米松组与普萘洛尔组比较，两组治愈率无明显差异(P &gt; 0.05)，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of treatment results among the 3 group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >I级(差)</th><th align="center" valign="middle" >II级(中)</th><th align="center" valign="middle" >III级(好)</th><th align="center" valign="middle" >IV级(优)</th><th align="center" valign="middle" >合计(例)</th><th align="center" valign="middle" >治愈率(%)</th></tr></thead><tr><td align="center" valign="middle" >倍他米松组</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >60.0</td></tr><tr><td align="center" valign="middle" >普萘洛尔组</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >57.9</td></tr><tr><td align="center" valign="middle" >联合组</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >90.9</td></tr></tbody></table></table-wrap><p>表3. 3组患儿治疗结果比较</p></sec><sec id="s7_3"><title>3.3. 不良反应分析</title><p>单纯普萘洛尔治疗组中有7例患儿在首次口服药物后出现心率减慢，经过临床观察后恢复正常。单纯复方倍他米松治疗组有6例患儿在注射治疗后出现术区局部肿胀，给予加压包扎后约1天时间恢复，2例出现烦躁。联合组中有3例患儿服药后出现心率减慢，未予特殊处理；2例患儿在注射后出现术区局部肿胀、渗血，给予加压包扎后逐渐缓解。所有患儿均未出现心动过缓、低血糖、哮喘、局部组织破溃、坏死等致治疗停止的严重不良反应。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>婴幼儿血管瘤是一种婴幼儿时期最常见的发生于皮肤及软组织的良性脉管肿瘤。1982年，JB Mulliken等首次根据血管内皮细胞的生物学特性将血管瘤重新分为血管瘤和脉管畸形两大类 [<xref ref-type="bibr" rid="hanspub.39270-ref11">11</xref>]，2018年ISSVA据此再次修订了该分类方法。其自然病程分为增生期、消退期、消退完成期三期。目前，其病因及来源尚不清楚，据报道可能与缺氧、早产、出生时低体重、血管内皮细胞生长因子A (VEGF-A)、胎盘生物学标记物(如GLUT-1)等潜在因素相关 [<xref ref-type="bibr" rid="hanspub.39270-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.39270-ref13">13</xref>]。</p><p>因大部分婴幼儿血管瘤存在自然消退的特点，以往许多学者认为可采取观察等待的策略(“wait-and-see”)而不进行治疗，但有部分患儿在血管瘤增殖过程中可能出现导致功能损害(眼、耳、呼吸道等部位)及容貌毁损甚至导致死亡的严重并发症 [<xref ref-type="bibr" rid="hanspub.39270-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.39270-ref14">14</xref>]，未经治疗的血管瘤在自然消退后可能残留瘢痕、色素脱失及沉着、毛细血管扩张、皮肤褶皱等退行性变 [<xref ref-type="bibr" rid="hanspub.39270-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.39270-ref16">16</xref>]，组织层面较深的血管瘤消退时间过长影响患儿的生理及心理健康等。近年来，随着医学的进步及对IH的认识进一步增加，部分学者开始对婴幼儿血管瘤患者进行风险性评估，根据累及部位及生长趋势分为三个等级：低风险、中风险、高风险 [<xref ref-type="bibr" rid="hanspub.39270-ref17">17</xref>]。并主张对中、高风险的血管瘤进行早期治疗，取得良好效果，且治疗越早效果越明显 [<xref ref-type="bibr" rid="hanspub.39270-ref18">18</xref>]，对于低风险的婴幼儿血管瘤依然可以采取观察等待的策略，但要密切随访，若瘤体出现迅速增长仍应尽早介入治疗 [<xref ref-type="bibr" rid="hanspub.39270-ref19">19</xref>]。</p><p>目前婴幼儿血管瘤的治疗方式大体可分为系统性药物治疗和局部药物治疗两大类，常用药物包括糖皮质激素(地塞米松等)、β受体阻滞剂(普萘洛尔等)、抗肿瘤药物(平阳霉素等)等 [<xref ref-type="bibr" rid="hanspub.39270-ref3">3</xref>]。基本治疗原则为延缓瘤体增殖速度、促进瘤体消退和减少预后残存。</p><p>普萘洛尔应用在心血管疾病的治疗上已有悠久历史，2008年法国医生L&#233;aut&#233;-Labr&#232;ze等在给充血性心力衰竭的患儿口服普萘洛尔时意外发现其在治疗IH上的作用，作用机制尚不完全清除，研究表明可能与β受体阻滞剂诱导血管收缩、降低VEGF基因表达、促进血管内皮细胞凋亡有关 [<xref ref-type="bibr" rid="hanspub.39270-ref20">20</xref>]。近年来，大量普萘洛尔治疗IH的研究证实，其疗效确切，已成为治疗婴幼儿血管瘤的一线疗法 [<xref ref-type="bibr" rid="hanspub.39270-ref14">14</xref>]。不良反应主要为缓慢性心律失常、低血压、低血糖、支气管痉挛、腹泻、烦躁等，但不良反应发生率极低且轻微，本研究仅有10例患儿在口服药物后出现一过性心率减慢，经观察后恢复，未给予特殊处理。本研究使用了国内外推荐的给药方式 [<xref ref-type="bibr" rid="hanspub.39270-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.39270-ref22">22</xref>]，使用普萘洛尔1.5~2 mg/kg∙d，“阶梯式给药”，即第一天给予1 mg/kg∙d，第二天给予1.5 mg/kg∙d，第三天增加至2 mg/kg∙d并维持使用，普萘洛尔随喂奶或进食时服用，有效避免了低血糖反应的发生。服药后进行严密心电血压检测，避免出现严重的心律失常及低血压。本组患儿对此种用药方案耐受性较好，未出现导致停药的不良反应，但对于部分低龄(&lt;2个月)和低体重(&lt;2 Kg)患儿应适当减少用药剂量 [<xref ref-type="bibr" rid="hanspub.39270-ref3">3</xref>]。</p><p>糖皮质激素应用于治疗婴幼儿血管瘤起源于上世纪六十年代，在此后的数十年间一直作为治疗婴幼儿血管瘤的一线药物，直至普萘洛尔在临床上广泛应用后而被取代，以往通过口服进行系统性治疗的方法用药时间较长且不良反应较多，包括医源性库欣综合征、胃肠道反应、电解质紊乱、精神症状、免疫抑制、延缓生长等，患儿家属顾虑较多，依从性较差。随后学者们开始使用瘤体内注射给药的方式进行治疗，并取得良好效果 [<xref ref-type="bibr" rid="hanspub.39270-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.39270-ref9">9</xref>]，此种方式简单易行，必要时可重复注射。关于激素类药物的选择多种多样，Kushner [<xref ref-type="bibr" rid="hanspub.39270-ref23">23</xref>] 将曲安奈德混合倍他米松磷酸钠进行注射，取得良好效果。其作用机制迄今未明，研究显示 [<xref ref-type="bibr" rid="hanspub.39270-ref24">24</xref>] 可能的机制为局部释放去甲肾上腺素导致血管收缩，减少瘤体内血供；竞争性抑制雌激素受体；与GR受体结合抑制VEGF分泌；直接抑制VEGF的促血管生成作用等。本次研究选用的复方倍他米松为一种长短效倍他米松的混合成品制剂，注射后短效的倍他米松磷酸钠迅速在局部发挥作用，长效的二丙酸倍他米松缓慢释放，作用可维持约2周。在进行注射治疗前，我们通过包裹对患儿进行固定，使用带针延长软管使针头稳定在瘤体内，采用多点注射的方式使药物在瘤体内均匀分布。此种方式可避免因药物误入其它组织而造成的栓塞和坏死。</p><p>单纯口服普萘洛尔和局部注射复方倍他米松都可用于婴幼儿血管瘤的治疗，但单独使用均存在缺点，普萘洛尔需长期口服才能达到满意效果。对于部分瘤体较大、侵袭较深的血管瘤可能需要多次重复注射。目前报道少见对于二者联合用药的疗效分析，本次研究中，联合组的治愈率和治疗时间均优于单独应用任一种药物，差异均有统计学意义(P &lt; 0.05)，普萘洛尔通过cAMP和丝裂原活化蛋白激酶调节作用于血管瘤干细胞，降低干细胞中VEGF的表达而使瘤体消退 [<xref ref-type="bibr" rid="hanspub.39270-ref18">18</xref>]。倍他米松则通过竞争性结合雌激素受体、与GR受体结合等抑制VEGF分泌，从而抑制血管内皮细胞增殖并促进凋亡 [<xref ref-type="bibr" rid="hanspub.39270-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.39270-ref25">25</xref>]。两种药物通过不同机制均可抑制瘤体生长、促进瘤体消退，二者联合使用发挥协同作用机制，降低了单一用药时间及减少了重复注射次数，不良反应也有所下降。</p><p>本研究认为，口服普萘洛尔联合复方倍他米松局部注射疗效肯定，不良反应较少，但目前仍缺少前瞻性多中心大样本的研究，对于停药时间、注射药物剂量和制配方式进行规范，所以需要我们进一步研究讨论。</p></sec><sec id="s9"><title>文章引用</title><p>耿 锐,耿向群,苏毅鹏,李丹怡,孙 晨,张 彬,陈振雨. 口服普萘洛尔联合复方倍他米松局部注射治疗婴幼儿血管瘤的疗效评价Efficacy Evaluation of Oral Propranolol Combined with Compound Betamethasone Local Injection in the Treatment of Infantile Hemangioma[J]. 临床医学进展, 2020, 10(12): 3069-3075. https://doi.org/10.12677/ACM.2020.1012460</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39270-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Hochman, M. (2014) Infantile Hemangiomas: Current Management. Facial Plastic Surgery Clinics of North America, 22, 509-521. &lt;br&gt;https://doi.org/10.1016/j.fsc.2014.07.003</mixed-citation></ref><ref id="hanspub.39270-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kilcline, C. and Frieden, I.J. (2008) Infantile Hemangiomas: How Common Are They? A Systematic Review of the Medical Literature. Pediatric Dermatology, 25, 168-173. &lt;br&gt;https://doi.org/10.1111/j.1525-1470.2008.00626.x</mixed-citation></ref><ref id="hanspub.39270-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南(2019版) [J]. 组织工程与重建外科杂志, 2019, 15(5): 277-317.</mixed-citation></ref><ref id="hanspub.39270-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hoeger, P.H., Harper, J.I., Baselga, E., et al. (2015) Treatment of Infantile Haemangiomas: Recommendations of a European Expert Group. European Journal of Pediatrics, 174, 855-865. &lt;br&gt;https://doi.org/10.1007/s00431-015-2570-0</mixed-citation></ref><ref id="hanspub.39270-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">杨浩, 舒强, 郭晓东. 婴幼儿血管瘤的治疗进展[J]. 临床小儿外科杂志, 2019, 18(8): 640-645.</mixed-citation></ref><ref id="hanspub.39270-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Léauté-Labrèze, C., de la Roque, E.D., Hubiche, T. and Boralevi, F. (2008) Propranolol for Severe Hemangiomas of Infancy. New England Journal of Medicine, 358, 2649-2651. &lt;br&gt;https://doi.org/10.1056/NEJMc0708819</mixed-citation></ref><ref id="hanspub.39270-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zarem, H.A. and Edgerton, M.T. (1967) Induced Resolution of Cavernous Hemangiomas Following Prednisolone Therapy. Plastic &amp; Reconstructive Surgery, 39, 76-83. &lt;br&gt;https://doi.org/10.1097/00006534-196701000-00010</mixed-citation></ref><ref id="hanspub.39270-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Sloan, G.M., Reinisch, J.F., Nichter, L.S., et al. (1989) Intralesional Corticosteroid Therapy for Infantile Hemangiomas. Plastic &amp; Reconstructive Surgery, 83, 459-467. &lt;br&gt;https://doi.org/10.1097/00006534-198903000-00009</mixed-citation></ref><ref id="hanspub.39270-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">张世仁, 仇雅璟, 蔡宜佐, 等. 婴幼儿血管瘤瘤体内注射药物治疗研究进展[J]. 中华整形外科杂志, 2019, 35(2): 201-204.</mixed-citation></ref><ref id="hanspub.39270-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Achauer, B., Chang, C.-J. and Vander Kam, V. (1997) Management of Hemangioma of Infancy: Review of 245 Patients. Plastic &amp; Reconstructive Surgery, 99, 1301-1308. &lt;br&gt;https://doi.org/10.1097/00006534-199705000-00014</mixed-citation></ref><ref id="hanspub.39270-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Mulliken, J.B. and Glowacki, J. (1982) Hemangiomas and Vascular Malformations in Infants and Children. Plastic &amp; Reconstructive Surgery, 69, 421-422. &lt;br&gt;https://doi.org/10.1097/00006534-198203000-00003</mixed-citation></ref><ref id="hanspub.39270-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Laken, P.A. (2016) Infantile Hemangiomas: Pathogenesis and Review of Propranolol Use. Advances in Neonatal Care, 16, 135-142. &lt;br&gt;https://doi.org/10.1097/ANC.0000000000000254</mixed-citation></ref><ref id="hanspub.39270-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Smith, C.J.F., Friedlander, S.F., Guma, M., et al. (2017) Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. Birth Defects Research, 109, No. 11. &lt;br&gt;https://doi.org/10.1002/bdr2.1023</mixed-citation></ref><ref id="hanspub.39270-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Léauté-Labrèze, C., Harper, J.I. and Hoeger, P.H. (2017) Infantile Haemangioma. Lancet, 390, 85-94.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(16)00645-0</mixed-citation></ref><ref id="hanspub.39270-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Bauland, C.G., Lüning, T.H., Smit, J.M., et al. (2011) Untreated Hemangiomas: Growth Pattern and Residual Lesions. Plastic and Reconstructive Surgery, 127, 1643-1648. &lt;br&gt;https://doi.org/10.1097/PRS.0b013e318208d2ac</mixed-citation></ref><ref id="hanspub.39270-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Couto, R.A., Maclellan, R.A., Zurakowski, D., et al. (2012) Infantile Hemangioma: Clinical Assessment of the Involuting Phase and Implications for Management. Plastic and Reconstructive Surgery, 130, 619-624.  
&lt;br&gt;https://doi.org/10.1097/PRS.0b013e31825dc129</mixed-citation></ref><ref id="hanspub.39270-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Luu, M. and Frieden, I.J. (2013) Haemangioma: Clinical Course, Complications and Management. British Journal of Dermatology, 169, 20-30. &lt;br&gt;https://doi.org/10.1111/bjd.12436</mixed-citation></ref><ref id="hanspub.39270-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, L., Wu, H.W., Yuan, W.E. and Zheng, J. (2017) Propranolol Therapy for Infantile Hemangioma: Our Experience. Drug Design, Development and Therapy, 11, 1401-1408. &lt;br&gt;https://doi.org/10.2147/DDDT.S134808</mixed-citation></ref><ref id="hanspub.39270-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">郑家伟. 婴幼儿血管瘤“等待观察”的治疗策略应予改变[J]. 中国口腔颌面外科杂志, 2012(2): 163-164.</mixed-citation></ref><ref id="hanspub.39270-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Storch, C.H. and Hoeger, P.H. (2010) Propranolol for Infantile Haemangiomas: Insights into the Molecular Mechanisms of Action. British Journal of Dermatology, 163, 269-274. &lt;br&gt;https://doi.org/10.1111/j.1365-2133.2010.09848.x</mixed-citation></ref><ref id="hanspub.39270-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">None (2008) More on Propranolol for Hemangiomas of Infancy. New England Journal of Medicine, 359, 2846-2847. &lt;br&gt;https://doi.org/10.1056/NEJMc086443</mixed-citation></ref><ref id="hanspub.39270-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形诊断和治疗指南(2016版) [J]. 组织工程与重建外科杂志, 2016, 12(2): 63-93.</mixed-citation></ref><ref id="hanspub.39270-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kushner, B.J. (1982) Intralesional Corticosteroid Injection for Infantile Adnexal Hemangioma. American Journal of Ophthalmology, 93, 496-506. &lt;br&gt;https://doi.org/10.1016/0002-9394(82)90140-4</mixed-citation></ref><ref id="hanspub.39270-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">位永娟, 周昉, 等. 糖皮质激素对血管瘤治疗机制的研究进展[J]. 中华妇幼临床医学杂志(电子版), 2008, 4(2): 131-138.</mixed-citation></ref><ref id="hanspub.39270-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">刘潜, 李静, 周德凯, 等. 糖皮质激素瘤内注射治疗婴幼儿血管瘤机理的研究[J]. 医学争鸣, 2007, 28(13): 1199-1201.</mixed-citation></ref></ref-list></back></article>